Zheng J, Cao H, Li Y, et al. - In patients suffering from ROS1 rearranged non-small cell lung cancer (NSCLC), researchers assessed if crizotinib is efficacious as a first-line therapy in this retrospective review of 56 patients managed with first-line crizotinib for ROS1-rearranged advanced NSCLC recruited from five hospitals in China. The participants median age was 53.0 years and the majority of cases (91.1%) had adenocarcinomas. Following first-line crizotinib therapy, the median progression free survival and the median overall survival were estimated to be 23.0 months and 60.0 months, respectively. In multivariable analysis, the only independent prognostic factor of progression free survival was >2 baseline metastatic organ involvement. Overall, Chinese patients with ROS1-rearranged advanced NSCLC benefited from first-line crizotinib treatment. G2032R mutation in the ROS1 kinase domain was connected with resistance to crizotinib.